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Consensus Statement
Arthroscopy Association of Canada
Position Statement on Intra-articular
Injections for Knee Osteoarthritis
Arthroscopy Association of Canada*†
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The Arthroscopy Association of Canada (AAC) recently
published guidelines pertaining to arthroscopic surgery as
a treatment for osteoarthritis (OA) of the knee. This was in
response to recent public interest surrounding the utility
and cost-effectiveness of arthroscopic surgery in this set-
ting. As part of these guidelines, the AAC recommends a
6- to 9-month trial of “appropriate and comprehensive non-
operative treatment.”53 A key component of nonoperative
strategies are intra-articular injections. The injections
available in Canada include corticosteroids, hyaluronic acid
(HA), platelet-rich plasma (PRP), and cellular-based ther-
apies, including bone marrow aspirate concentrate
(BMAC). In light of emerging evidence, the AAC endeav-
ored to synthesize the most relevant and up-to-date data
pertaining to the use of these agents in the treatment of
knee OA. Based on the highest quality available evidence
as well as the expert opinion of experienced clinicians,
recommendations to help guide clinical practice are pro-
posed. The grading of recommendations is categorized
according to the scale developed by Wright et al54 and sub-
sequently expanded by Stevens et al47 (Table 1). It is under-
stood that the ultimate decision-making process will
involve the treating clinician as well as the patient and will
take into consideration all associated risks and benefits.
CORTICOSTEROIDS
Synthetic corticosteroids have been used in clinical prac-
tice for over 50 years. Their anti-inflammatory effect is
caused primarily by their ability to modulate the expres-
sion of lymphocytes and cytokines.16 They also serve to
increase the viscosity and HA concentration of synovial
fluid.24 The most common injectable corticosteroids avail-
able include methylprednisolone and triamcinolone. They
are often combined with a local anesthetic to decrease the
incidence of a postinjection flare reaction, which can occur
in 3% to 25% of injections.21
The most recent recommendations from the American
Academy of Orthopaedic Surgeons (AAOS) synthesized
the available literature up to 2013 and concluded that
there is “inconclusive evidence to recommend for or
against the use of intra-articular corticosteroids to treat
knee OA.”28 A 2015 Cochrane review found corticosteroids
to be more beneficial than a control in reducing pain and
improving function in the early (<6 weeks) postinjection
period, with no benefit observed beyond 6 months.29
However, the small sample size and poor methodological
quality of the studies included significantly reduced
the strength of these findings.29 More recently,
McAlindon et al38 aimed specifically to determine the del-
eterious effects of repeated corticosteroid injections in
patients with knee OA. Patients were randomized to
receive intra-articular triamcinolone or saline injections
every 3 months for 2 years. The authors showed no differ-
ence in pain scores between the 2 groups but an increase in
cartilage volume loss on magnetic resonance imaging in
the corticosteroid cohort.38 Finally, a prospective multi-
center trial evaluated the factors affecting the treatment
response to intra-articular corticosteroids in patients with
knee OA. That study revealed that patients with less
severe OA (Kellgren-Lawrence grades 1-2) were more
likely to achieve and maintain improvement up to 3
months after the injection. Obesity was also shown to
decrease the treatment effect.37
The evidence suggests that intra-articular corticoster-
oids possess moderate benefit in reducing pain and
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improving function in the early stages of knee OA. The
effects are most pronounced in the early time frame after
injection and do not persist beyond 6 months. Although the
risk of adverse events is relatively low, repeated injections
should be performed with caution because of a risk of fur-
ther cartilage volume loss.
Recommendation: Intra-articular corticosteroid
injections provide short-term, moderate pain relief
and the restoration of function and offer a cost-
effective treatment option in patients with early
knee OA. Strength of recommendation: Good – A
HYALURONIC ACID
HA is a naturally occurring polymer that has been shown to
increase the viscosity of synovial fluid as well as the com-
pressive strength of articular cartilage.41 In the setting of
OA, it acts to decrease inflammation by reducing oxidative
stress and inhibiting phagocytosis of macrophages.30 HA has
been approved in Canada for the treatment of mild to mod-
erate OA of the knee since 1992. Accordingly, a number of
preparations have become available, differing primarily in
their method of production, molecular weight, cross-linking,
and administration.39 High–molecular weight (HMW) HA
has been defined as greater than 3000 kDa, although some
studies suggest that 6000 kDa is more likely to affect out-
comes.3,6 Overall, HA possesses a relatively low-risk profile,
with adverse reactions such as infection and granulomatous
inflammation reported in 4% to 13% of injections.2,10
Numerous randomized controlled trials (RCTs) have
investigated the efficacy of HA in recent years. Unfortu-
nately, significant heterogeneity in the trial design,
preparation employed, and outcome measures assessed
has challenged the interpretation of the results. In
2006, a Cochrane review concluded that HA provides
pain reduction and improvement in physical function
and is thus a viable treatment option in younger patients
with less severe OA.9 However, the 2013 AAOS Clinical
Practice Guidelines27 cited a strong recommendation
against the use of HA for the treatment of knee OA.
Recent studies have focused on the intrinsic properties
of HA that influence outcomes. A systematic review by
Rutjes et al43 compared HA with placebo or no interven-
tion. Upon subgroup analysis, HMW HA preparations
showed both a statistically and clinically significant
reduction in pain.43 Subsequent meta-analyses have con-
firmed these results.3,6 A meta-analysis by Jevsevar
et al26 reported that highly cross-linked HA had a signif-
icantly greater treatment effect size than non–cross
linked HA at 26 weeks after injection. Xing et al55 con-
ducted a systematic review of 12 meta-analyses and con-
cluded that HA is an effective intervention for the
treatment of knee OA without an increased risk of
adverse events. In 2017, a group of Canadian clinicians
and scientists met to review all meta-analyses of RCTs
published between 2012 and 2016 comparing HA with
placebo or no intervention.10 They concluded that intra-
articular HA resulted in improved pain, function, and
stiffness for up to 26 weeks in patients with mild to
moderate knee OA. Furthermore, HMW HA was superior
to low–molecular weight (LMW) HA and surpassed the
threshold of the minimal clinically important difference
(MCID).10 Similarly, a 2018 systematic review of all non-
operative treatments for knee OA concluded that, after
accounting for the intra-articular placebo effect, HMW
HA had the most precise treatment effect, surpassing the
MCID.50
Although controversy persists in the literature, more
recent evidence suggests that HA is superior to placebo or
no intervention in providing pain relief and improving
function in patients with knee OA. HMW and highly
cross-linked HA are likely more effective than LMW and
non–cross linked HA, respectively. The effects are most
pronounced in mild to moderate disease and in the first
26 weeks after injection.
TABLE 1
Grades of Recommendation for Summaries or Reviews of Orthopaedic Surgical Studies and a Proposed Subscale
Designed to Differentiate Evidence for Indications Receiving a Grade of Recommendation of Ca
Grades of Recommendation Description
A Good evidence (level 1 studies with consistent findings) for or against recommending an intervention
B Fair evidence (level 2 or 3 studies with consistent findings) for or against recommending an intervention
C Conflicting or poor-quality evidence (level 4 or 5 studies) not allowing a recommendation for or against
an intervention
I Insufficient evidence to make a recommendation
Proposed Subscale Description
Cf Representing literature “for,” or in support of, a surgical intervention
Cu Representing literature “against,” or not in support of, a surgical intervention
Ce Representing conflicting literature, some of which is in support of a surgical intervention and some of which
is not in support of a surgical intervention
aFrom Stevens MS, Legay DA, Glazebrook MA, Amirault D. The evidence for hip arthroscopy: grading the current indications.
Arthroscopy. 2010;26(10):1370-1383.47
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Recommendation: Intra-articular injections of
HMW HA provide improved pain relief and the res-
toration of function compared with placebo and can
be considered in patients with mild to moderate
knee OA. Strength of recommendation: Good – A
PLATELET-RICH PLASMA
PRP was initially defined as “a volume of plasma with an
above-baseline concentration of platelets.”36 This definition
has since changed, requiring PRP to contain a minimum of
1 million platelets per milliliter, which is thought to be the
threshold required to stimulate targeted cells.36,40 PRP is
derived from autogenous whole blood centrifugation, which
separates out red blood cells, leaving PRP. Once injected,
platelets degranulate, releasing proteins, cytokines, and
growth factors that help regulate the inflammatory process
and stimulate cell proliferation.20,25 A number of PRP prep-
aration systems are commercially available, although each
yields differences in platelet capture efficiency and the con-
centration of additional constituents (ie, white blood cells,
growth factors, etc).19 In addition to the heterogeneity
attributed to the preparation system, the PRP composition
can also be affected by exercise and the time of day.5 This
significant heterogeneity between preparations makes the
interpretation of clinical results and pooling of data for
meta-analyses extremely challenging.
In 2013, the AAOS Clinical Practice Guidelines reported
insufficient evidence to support the use of PRP for knee
OA.28 However, research surrounding the use of PRP for
knee OA has progressed in recent years. Several RCTs have
compared PRP with placebo (saline) and other intra-
articular therapies, including HA and corticosteroids. A
recent meta-analysis evaluated 10 RCTs comparing PRP
with placebo (saline) and HA.18 Compared with placebo
(saline), PRP showed significantly better improvements in
pain and function at both 6 and 12 months, with effect sizes
exceeding the MCID. While PRP and HA had similar pos-
itive effects in improving pain and function at 6 months,
PRP demonstrated superior outcomes to HA at 12 months
for both pain relief and functional improvement. The effect
sizes for both measures also exceeded the MCID. Along the
same lines as this meta-analysis, a recent RCT by Cole et al17
evaluated 111 patients with knee OA who received either
leukocyte-poor PRP or HA. Although they showed no differ-
ence inthe primaryoutcome(Western Ontario andMcMaster
Universities Osteoarthritis Index [WOMAC]), improvements
favoring leukocyte-poor PRP wereseen inInternational Knee
Documentation Committee and visual analog scale scores.17
Additional studies have also shown that patient age and the
stage of OA can influence the efficacy of PRP, with younger
patients with lower grade OA (Kellgren-Lawrence grades
1-2) demonstrating comparatively better outcomes.11,22
Overall, PRP has been shown to have a low risk of adverse
reactions, with studies showing no difference between intra-
articular injections of PRP and placebo.31
Despite the improved quality of evidence to provide some
support for PRP in knee OA, heterogeneity in outcomes
exists, and many questions remain. There is still little
information on the optimal preparation system and prepara-
tion method, composition (ie, leukocyte-rich or leukocyte-
poor), clinical dosage required, and durability of achieved
results. Combined with the aforementioned heterogeneity
introduced by the different commercially available prepara-
tion systems, a consensus for recommended use remains
challenging.
Recommendation: PRP injection has the potential
to provide improvements in pain and functional out-
comes up to 1 year after the injection in patients with
mild to moderate knee OA. Evidence of efficacy in
advanced OA is lacking. Given the heterogeneity of
the evidence as well as the lack of consensus on the
ideal PRP preparation method and composition, we
cannot recommend for or against the use of PRP
until further high-quality clinical studies become
available. Strength of recommendation: Cf
CELLULAR-BASED THERAPIES: BMAC
Cellular-based therapies using undifferentiated progenitor
cells, or stem cells, have become an attractive potential
option for treating OA and chondral injuries of the knee.
The rationale for their use is that these mesenchymal stem
cells (MSCs) may be able to differentiate into cells of a
chondrogenic lineage, contributing to restorative healing.49
Some studies have even reported that they possess the
capacity to help regenerate subchondral bone in small
defects.34 However, other theories attribute their clinical
effect to their strong anti-inflammatory properties rather
than their regenerative potential.34 Caplan13 suggested
changing the name to “medicinal signaling cells” to reflect
their ability to migrate to sites of injury and secrete thera-
peutic (“medicinal”) factors.
MSCs can be isolated from a variety of tissues, including
adipose, amniotic fluid/membrane, and bone marrow.40
Presently, Health Canada has only approved stem cell use
in the treatment of certain oncological processes. Health
Canada does not currently regulate the use of stem cells
in a homologous manner with minimal manipulation, allow-
ing unapproved use for certain musculoskeletal conditions.
This is akin to the regulations by the Food and Drug Admin-
istration (FDA) in the United States. As a result of the con-
trol of these regulatory bodies, the use of cultured or
manipulated stem cells has been limited to controlled phase
1/2 clinical studies. Bone marrow–derived MSCs have been
the primary focus of most studies, while adipose-derived
cells and the stromal vascular fraction are starting to receive
more attention. While there are several small series demon-
strating clinical and radiological improvements after intra-
articular injections of stem cells from each of these sources
for the treatment of knee OA, the small sample sizes and
heterogeneity of patients and cellular concentrations make
it difficult to draw meaningful conclusions.35
In recent years, BMAC without additives, culturing, or
expansion has been considered to comply with Health
Canada and FDA standards of “minimal manipulation.”45
As such, it has been increasingly used, as it allows for sim-
ple retrieval and the utilization of bone marrow–derived
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MSCs, despite the fact that MSCs comprise only a minor
proportion of BMAC (0.001%-0.01%).15 It may be that the
various cellular components of BMAC are equally or more
important than the MSCs themselves. This is particularly
true of interleukin-1 receptor antagonist (IL-1ra), which is
present in high concentrations and acts as a potent anti-
inflammatory agent by inhibiting IL-1 catabolism.14 Two
recent RCTs compared BMAC with placebo (saline injec-
tion) in the treatment of knee OA.44,45 Both identified sig-
nificant improvements in pain and quality of life 12 months
after BMAC injection; however, these results did not differ
significantly from the response to saline injections in the
contralateral knee. Another study demonstrated that there
was a significant association between a higher Kellgren-
Lawrence grade and inferior outcomes.32 Additional stud-
ies have also utilized BMAC; however, the interpretation of
the results has remained challenging, as BMAC is often
utilized with concomitant surgical procedures or interven-
tions.51 Furthermore, there is no consensus on the BMAC
harvest technique, concentration, or effective clinical dos-
age. As a result, consensus recommendations are similarly
not feasible, and current use should be limited to clinical
trials rather than routine clinical use. While we do recog-
nize the potential benefit of biological therapies, rigorous,
well-designed clinical trials are needed to establish the
safety, efficacy, and cost-effectiveness of these potential
treatments before widespread adoption.
Recommendation: There is insufficient evidence
to support the use of MSCs or BMAC in the treatment
of knee OA. As such, MSC and BMAC injections
should be limited to registered controlled trials, and
we cannot recommend their use in routine clinical
practice until further evidence becomes available.
Strength of recommendation: Insufficient – I
COMBINATION THERAPIES
The combination of various intra-articular injection thera-
pies has been investigated in recent years. More specifi-
cally, 4 combinations have been reported in the literature:
HA and corticosteroids, HA and PRP, PRP and corticoster-
oids, and PRP and MSCs.
The most frequently described combination therapy is
HA with corticosteroids. Studies have shown that intra-
articular corticosteroid injections have a rapid onset of
action with a short overall duration, while HA injections
have a slower onset but provide longer lasting benefits.6,7
Accordingly, combining HA with corticosteroids may offer
quicker and more durable pain relief than either agent
alone. A 2019 meta-analysis by Smith et al46 identified
8 RCTs comparing intra-articular injections of combined
HA and corticosteroids to HA alone in the treatment of knee
OA. The HA plus corticosteroid group showed improved
WOMAC pain scores at 2 to 4 weeks, 24 to 26 weeks, and
52 weeks after injection compared with the HA-only group.
There were no significant differences in pain scores at
intermediate follow-up (6-13 weeks) or in treatment-
related adverse events at any time point. Two more recent
RCTs have since been published. Both studies report
improvement in WOMAC pain scores for combined HA and
corticosteroid injections at earlier time points (6-12 weeks),
with no difference at longer term follow-up (26 weeks).23,52
Despite the promising results favoring intra-articular
injections of combined HA and corticosteroids in the treat-
ment of knee OA, these findings must be met with caution,
as they are limited by the small number of high-quality
studies, heterogeneity in reported outcomes, and paucity
of data comparing HA and corticosteroids with placebo.
Concerns regarding the potential acceleration of cartilage
loss with serial cortisone injections outlined above also
apply to combination therapy.
The use of HA in combination with PRP has also been
reported in recent years. As outlined above, both agents
have shown benefit in the treatment of early knee OA,
although they differ in their mechanism of action. Basic
science studies confirm that PRP, along with its anti-
inflammatory and immunomodulatory role, can also stim-
ulate HA production. Accordingly, PRP with HA may have
a synergistic effect in the creation of a favorable medium for
cellular healing, and combination therapy may be superior
to a single agent alone.4,48 Unfortunately, this hypothesis
has not been borne out in the literature. Current studies
regarding intra-articular injections of combined HA and
PRP show inconsistent results and are of poor methodolog-
ical quality.1,33,56 In the absence of high-level evidence, we
cannot recommend combination therapy with HA and PRP
at this time.
Studies investigating combination therapies with PRP
and corticosteroids and with PRP and MSCs are limited to
small case series and pilot studies and are not of sufficient
quality to warrant further consideration at this time.8,12,42
Recommendation: (1) Intra-articular injections of
combined HA and corticosteroids in the setting of
knee OA can provide significant improvement in
pain outcomes and may provide a more rapid onset
and longer duration of action than either therapy
alone. Strength of recommendation: Fair – B
(2) There is insufficient evidence to support other
combinations of intra-articular injection therapy.
Strength of recommendation: Insufficient – I
POSITION STATEMENT CONCLUSIONS
1. Intra-articular corticosteroid injections provide short-
term, moderate pain relief and the restoration of
function.29
2. Intra-articular HA provides improvement in pain,
function, and stiffness for up to 26 weeks after an
injection in patients with mild to moderate knee OA.
It is safe with a low risk of adverse events.9,43,55
3. HMW HA is superior to LMW HA, with a treatment
effect surpassing the MCID.50 Similarly, highly cross-
linked HA is more effective than non–cross linked
HA.26
4. PRP is safe with a low risk of adverse events. Although
some studies identify the potential to improve pain
and function, its therapeutic effect in early knee OA
has been shown to be highly variable and without
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clear proven benefits. As such, there is insufficient
evidence at this time to recommend for or against the
use of PRP.18,31
5. There is insufficient evidence comparing PRP com-
positions (ie, leukocyte-rich vs leukocyte-poor) to
make definitive recommendations for the treatment
of knee OA.
6. There is insufficient evidence to recommend MSCs/
BMAC in the treatment of knee OA.
7. Rigorous, well-designed clinical trials are needed to
establish the safety, efficacy, and cost-effectiveness
of BMAC/MSCs before widespread adoption.
8. Combination therapy with HA and corticosteroids has
been shown to significantly reduce pain in knee OA,
with a more rapid onset of action than HA alone.46
9. The use of any injectables is most effective in patients
with mild to moderate knee OA (Kellgren-Lawrence
grades 1-2).
10. The use of injectables for knee OA should take into
consideration evidence-based research and a discus-
sion of the efficacy, safety, and cost-effectiveness of
such treatments within the patient’s means.
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